FDA approves cabozantinib to treat rare type of thyroid cancer

Article

FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.